ABEO Quote, Financials, Valuation and Earnings

Central Vermont Public Service Corp. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of --. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Central Vermont Public Service Corp.'s return on equity of --.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 303.97%. On the other hand Central Vermont Public Service Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Abeona Therapeutics, Inc. has higher upside potential than Central Vermont Public Service Corp., analysts believe Abeona Therapeutics, Inc. is more attractive than Central Vermont Public Service Corp..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Central Vermont Public Service Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Central Vermont Public Service Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Central Vermont Public Service Corp. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are larger than Central Vermont Public Service Corp. quarterly revenues of --. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than Central Vermont Public Service Corp.'s net income of --. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.39x while Central Vermont Public Service Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 690.83x versus -- for Central Vermont Public Service Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 12.65%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Electromed, Inc.'s return on equity of 18.89%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 303.97%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.79%. Given that Abeona Therapeutics, Inc. has higher upside potential than Electromed, Inc., analysts believe Abeona Therapeutics, Inc. is more attractive than Electromed, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.39x while Electromed, Inc.'s PE ratio is 30.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 690.83x versus 3.82x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nuwellis, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of 21.11%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat Nuwellis, Inc.'s return on equity of -1004.06%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 303.97%. On the other hand Nuwellis, Inc. has an analysts' consensus of $13.00 which suggests that it could grow by 21288.91%. Given that Nuwellis, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe Nuwellis, Inc. is more attractive than Abeona Therapeutics, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison Nuwellis, Inc. has a beta of -0.165, suggesting its less volatile than the S&P 500 by 116.484%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. Nuwellis, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than Nuwellis, Inc. quarterly revenues of $2.2M. Abeona Therapeutics, Inc.'s net income of -$5.2M is lower than Nuwellis, Inc.'s net income of $468K. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.39x while Nuwellis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 690.83x versus 0.58x for Nuwellis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed, Inc. has a net margin of -- compared to Abeona Therapeutics, Inc.'s net margin of -120220%. Abeona Therapeutics, Inc.'s return on equity of 88.36% beat PAVmed, Inc.'s return on equity of 8.75%.

Abeona Therapeutics, Inc. has a consensus price target of $20.64, signalling upside risk potential of 303.97%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 2980.42%. Given that PAVmed, Inc. has higher upside potential than Abeona Therapeutics, Inc., analysts believe PAVmed, Inc. is more attractive than Abeona Therapeutics, Inc..

Abeona Therapeutics, Inc. has a beta of 1.120, which suggesting that the stock is 11.973% more volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.095, suggesting its more volatile than the S&P 500 by 9.503%.

Abeona Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Abeona Therapeutics, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.

Abeona Therapeutics, Inc. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. Abeona Therapeutics, Inc.'s net income of -$5.2M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Abeona Therapeutics, Inc.'s price-to-earnings ratio is 4.39x while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Abeona Therapeutics, Inc. is 690.83x versus 274.73x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.